In November 2015, the FDA approved a new device for artificial reproduction. This new device - INVOcell® - is meant to ease both the cost and effort in traditional in-vitro fertilization (IVF). The INVOcell® is an intravaginal culture system, which is “a prescription device intended for preparing, holding, and transferring human gametes or embryos during intravaginal in vitro fertilization or intravaginal culture procedures.” INVO Bioscience, the company behind INVOcell®, offers its device as “a more natural, cultural, or religious appropriate choice.” Initially, INVOcell® may meet the guidelines for natural human conception in accordance with Roman Catholic magisterial teaching, particularly with conception occurring in vivo. Is it a licit option, however? Is conception in vivo enough to satisfy Catholic teaching? In this paper, I explore the various elements of INVOcell® as a reproductive technology in light of Catholic reproductive teaching. I argue that while INVOcell® solves one ethical problem - that of conception in vivo - it does not address the full, unnecessary risks to the embryo(s) created in the process. I conclude that while INVOcell® is preferred to traditional IVF, it does not fully satisfy Catholic teaching and is therefore not an appropriate option for Catholics seeking reproductive treatments.